The Institute for Clinical and Economic Review (ICER) has published the report Unsupported Price Increases (UPI) of prescription drugs in the USA. 11 December 2023
Industry has renewed its criticism of the UK government after the publication of new terms for the statutory scheme for branded medicines. 5 December 2023
A report from researchers at The University of New South Wales, in Australia, highlights significant progress towards the elimination of hepatitis C, while caut 4 December 2023
Several Latin American countries, given their processes of political change, are immersed in deep discussions about transforming their health systems, writes Th 29 November 2023
The National Institute for Health and Care Excellence (NICE) has opted against recommending Crysvita (burosumab) to treat adults in England and Wales who have a 29 November 2023
Industry lobbyist the Pharmaceutical Research and Manufacturers of America (PhRMA) has criticized greater use of prior authorization in Medicaid. 29 November 2023
Tense negotiations between the UK Government and the pharmaceutical industry over a new drug pricing framework have concluded with a far-reaching agreement. 20 November 2023
The National Institute for Health and Care Excellence (NICE) has issued its Final Draft Guidance (FDG) recommending Jardiance (empagliflozin) as an option for t 17 November 2023
GLP-1 agonists are transforming the way cardiometabolic disorders are treated, with new approvals in obesity opening the door to significant new treatment oppor 17 November 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.